In 2024, South Africa and Mozambique had the highest number of deaths due to AIDS worldwide, with around ** thousand and ** thousand such deaths, respectively. African countries account for eight of the top 10 countries with the highest number of AIDS-related deaths worldwide. AIDS-related deaths worldwide have been gradually declining over the past decade, decreasing from *** million deaths in 2010 to *** thousand deaths in 2024. HIV/AIDS HIV (human immunodeficiency virus) is an infectious sexually transmitted disease that is transmitted via exposure to infected semen, blood, vaginal and anal fluids and breast milk. HIV weakens the human immune system, resulting in the affected person being unable to fight off opportunistic infections. The top 15 countries worldwide with the highest prevalence of new HIV infections as of 2024 were all African. HIV treatment Although there is currently no effective cure for HIV, death can be prevented by taking HIV antiretroviral therapy (ART). Access to antiretroviral therapy worldwide has significantly increased in the past decade. As of 2024, around **** million people with HIV worldwide were receiving ART. The countries with the highest percentage of HIV-infected children who were receiving ART were Eswatini, Kenya, and Lesotho.

HIV/AIDS deaths in the U.S. have dropped significantly in recent years. In 1995, the death rate from HIV per 100,000 people was 16.2. That number has since decreased to 1.3 per 100,000 as of 2023. The reduction in the HIV death rate in the U.S. can be attributed to an increase in access to HIV medications. HIV/AIDS in the U.S. Human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) cause a systemic viral infection that damages the immune system. AIDS is a syndrome that is caused by HIV. AIDS is when the immune system is severely weakened by HIV and the body can no longer fight off infections. Among all U.S. states, Georgia, followed by Florida and Louisiana, had the highest rates of new HIV diagnoses in 2022. HIV/AIDS treatments in the U.S. HIV/AIDS treatments include antiretroviral medications to reduce the levels of HIV within the body. The largest funders for HIV/AIDS medications and research are the National Institutes of Health (NIH) and the Ryan White Program. The top HIV drug worldwide, based on revenue generated in 2023 was Biktarvy. Around the world, access to antiretroviral treatment has increased dramatically in recent years, a huge step in reducing the number of HIV-related deaths. There is currently no cure for HIV.

UNAIDS estimated that there were some ******* people worldwide that died from acquired immune deficiency syndrome (AIDS) in 2024. This statistic depicts the total number of annual AIDS-related deaths worldwide from 2000 to 2024. HIV/AIDS burden A majority of countries with the highest burden due to HIV and AIDS are in Africa- in 2024, the highest number of AIDS-related deaths occurred in South Africa and Mozambique and the highest prevalence of HIV was found in Eswatini. Although access to life-saving antiretroviral therapy treatment (ART) has increased globally over recent years, many individuals living with HIV still lack access to ART. Barriers and interventions In part due to the development of ART, the number of people living with HIV worldwide is continuing to increase, reaching almost ** million in 2024. Important public health measures to combat the burden of the disease include a combination of biomedical and behavioral interventions such as pre- and post-exposure prophylaxis, and context-specific structural interventions to reduce barriers to supplies and education. One prominent barrier faced by those living with HIV is stigma, which can often cause disadvantages in many areas of life, including employment, use of health services, and social support.

The mortality estimate methodology is fully described elsewhere and takes into consideration parameters such as ART coverage. For example, HIV associated mortality in Mozambique also reflects injection drug user driven epidemic.ART coverage calculated using 2013 reported people on ART/people estimated to be living with HIV in 2013.** Published guidelines as of December 2014; WHO 2013 Guidelines recommend

ART not only saves lives but also gives a chance for people living with HIV/AIDS to live long lives. Without ART very few infected people survive beyond ten years.1

Today, a person living in a high-income country who started ART in their twenties can expect to live for another 46 years — that is well into their 60s.2

While the life expectancy of people living with HIV/AIDS in high-income countries has still not reached the life expectancy of the general population, we are getting closer to this goal.3

The combination of antiretroviral drugs which make-up ART have progressively improved. Recent research shows that a person who started ART in the late 1990s would be expected to live ten years less than a person who started ART in 2008.4 This increase goes beyond the general increase in life expectancy in that period and reflects the improvements in ART — fewer side effects, more people following the prescribed treatment, and more support for the people in need of ART.

As of 2023, South Africa was the country with the highest number of people living with HIV in Africa. At that time, around 7.7 million people in South Africa were HIV positive. In Mozambique, the country with the second-highest number of HIV-positive people in Africa, around 2.4 million people were living with HIV. Which country in Africa has the highest prevalence of HIV? Although South Africa has the highest total number of people living with HIV in Africa, it does not have the highest prevalence of HIV on the continent. Eswatini currently has the highest prevalence of HIV in Africa and worldwide, with almost 26 percent of the population living with HIV. South Africa has the third-highest prevalence, with around 18 percent of the population HIV positive. Eswatini also has the highest rate of new HIV infections per 1,000 population worldwide, followed by Lesotho and South Africa. However, South Africa had the highest total number of new HIV infections in 2023, with around 150,000 people newly infected with HIV that year. Deaths from HIV in Africa Thanks to advances in treatment and awareness, HIV/AIDS no longer contributes to a significant amount of death in many countries. However, the disease is still the fourth leading cause of death in Africa, accounting for around 5.6 percent of all deaths. In 2023, South Africa and Nigeria were the countries with the highest number of AIDS-related deaths worldwide with 50,000 and 45,000 such deaths, respectively. Although not every country in the leading 25 for AIDS-related deaths is found in Africa, African countries account for the majority of countries on the list. Fortunately, HIV treatment has become more accessible in Africa over the years and now up to 95 percent of people living with HIV in Eswatini are receiving antiretroviral therapy (ART). Access to ART does vary from country to country, however, with around 77 percent of people who are HIV positive in South Africa receiving ART, and only 31 percent in the Congo.

The states with the highest rates of HIV diagnoses in 2022 included Georgia, Louisiana, and Florida. However, the states with the highest number of people with HIV were Texas, California, and Florida. In Texas, there were around 4,896 people diagnosed with HIV. HIV/AIDS diagnoses In 2022, there were an estimated 38,043 new HIV diagnoses in the United States, a slight increase compared to the year before. Men account for the majority of these new diagnoses. There are currently around 1.2 million people living with HIV in the United States. Deaths from HIV The death rate from HIV has decreased significantly over the past few decades. In 2023, there were only 1.3 deaths from HIV per 100,000 population, the lowest rate since the epidemic began. However, the death rate varies greatly depending on race or ethnicity, with the death rate from HIV for African Americans reaching 19.2 per 100,000 population in 2022, compared to just three deaths per 100,000 among the white population.

BackgroundSince the first HIV/AIDS case appeared in 1980s, HIV/AIDS has been the focus of international attention. As a major public health problem, there are epidemiological uncertainties about the future of HIV/AIDS. It is important to monitor the global statistics of HIV/AIDS prevalence, deaths, disability adjusted life years (DALYs), and risk factors for adequate prevention and control.MethodsThe Global Burden of Disease Study 2019 database was used to analyze the burden of HIV/AIDS in 1990–2019. By extracting global, regional, and national data on HIV/AIDS prevalence, deaths, and DALYs, we described the distribution by age and sex, explored the risk factors, and analyzed the trends in HIV/AIDS.ResultsIn 2019, there were 36.85 million HIV/AIDS cases (95% UI: 35.15–38.86 million), 863.84 thousand deaths (95% UI: 78.61–99.60 thousand), and 47.63 million (95% UI: 42.63–55.65 million) DALYs. The global age-standardized HIV/AIDS prevalence, death, and DALY rates were 454.32 (95% UI: 433.76–478.59), 10.72 (95% UI: 9.70–12.39), and 601.49 (95% UI: 536.16–703.92) per 100,000 cases, respectively. In 2019, the global age-standardized HIV/AIDS prevalence, death, and DALY rates increased by 307.26 (95% UI: 304.45–312.63), 4.34 (95% UI: 3.78–4.90), and 221.91 (95% UI: 204.36–239.47) per 100,000 cases, respectively, compared to 1990. Age-standardized prevalence, death, and DALY rates decreased in high sociodemographic index (SDI) areas. High age-standardized rates were observed in low sociodemographic index areas, while low age-standardized rates were observed in high sociodemographic index areas. In 2019, the high age-standardized prevalence, death, and DALY rates were predominant in Southern Sub-Saharan Africa, and global DALYs peaked in 2004 and subsequently decreased. The highest global HIV/AIDS DALYs were in the 40–44 age group. The main risk factors affecting HIV/AIDS DALY rates included behavioral risks, drug use, partner violence, and unsafe sex.ConclusionsHIV/AIDS disease burden and risk factors vary by region, sex, and age. As access to health care increases across countries and treatment for HIV/AIDS infection improves, the HIV/AIDS disease burden is concentrated in areas with low SDIs, particularly in South Africa. Regional differences should be fully considered to target optimal prevention strategies and treatment options based on risk factors.

Tuberculosis (TB) and HIV/AIDS are public health concerns in Papua New Guinea (PNG). This study examines TB and HIV/AIDS mortalities and associated sociodemographic factors in PNG. Method: As part of a longitudinal study, verbal autopsy (VA) interviews were conducted using the WHO 2016 VA Instrument to collect data of 926 deaths occurred in the communities within the catchment areas of the Comprehensive Health and Epidemiological Surveillance System from 2018-2020. InterVA-5 cause of deaths analytic tool was used to assign specific causes of death (COD). Multinomial logistic regression analyses were conducted to identify associated sociodemographic factors, estimate odds ratios (OR), 95% confidential intervals and p-values. Result: TB and HIV/AIDS were the leading CODs from infectious diseases, attributed to 9% and 8% of the total deaths, respectively. Young adults (25-34 years) had the highest proportion of deaths from TB (20%) and the risk of dying from TB among this age group was five times more likely than those aged 75+ years (OR: 5.5 [1.4-21.7]). Urban population were 46% less likely to die from this disease compared rural ones (OR: 0.54 [0.3-1.0]). People from middle household wealth quintile were three times more likely to die from TB than those in the richest quintile (OR: 3.0 [1.3-7.4]). Young adults also had the highest proportion of deaths to HIV/AIDS (18%) and were nearly seven times more likely to die from this disease compared with those aged 75+ years (OR: 6.7 [1.7-25.4]). Males were 48% less likely to die from HIV/AIDS than females (OR: 0.52 [0.3-0.9]). The risk of dying from HIV/AIDS in urban population was 54% less likely than their rural counterparts (OR: 0.46 [0.2-0.9]). Conclusion: TB and HIV/AIDS interventions are needed to target high-risk and vulnerable populations to reduce premature mortality from these diseases in PNG.

In 2023, the death rate from HIV was highest among those aged 60 to 64 years, with around **** deaths per 100,000 population. This statistic shows the death rate from HIV in the U.S. in 2023, by age, per 100,000 population.

Death rate of a population adjusted to a standard age distribution. As most causes of death vary significantly with people's age and sex, the use of standardised death rates improves comparability over time and between countries, as they aim at measuring death rates independently of different age structures of populations. The standardised death rates used here are calculated on the basis of a standard European population (defined by the World Health Organization). Detailed data for 65 causes of death are available in the database (under the heading 'Data').

In 2023, the death rate from HIV was highest among African Americans, with around 18 deaths per 100,000 population. This statistic shows the death rate from HIV in the U.S. in 2023, by race and ethnicity, per 100,000 population.

Death rate of a population adjusted to a standard age distribution. As most causes of death vary significantly with people's age and sex, the use of standardised death rates improves comparability over time and between countries, as they aim at measuring death rates independently of different age structures of populations. The standardised death rates used here are calculated on the basis of a standard European population (defined by the World Health Organization). Detailed data for 65 causes of death are available in the database (under the heading 'Data').

This is the replication kit for "Evidence and Lessons on the Health Impacts of Public Health Funding from the Fight against HIV/AIDS". HIV/AIDS has been one of the largest public health crises in recent history, and the U.S. federal government has spent hundreds of billions of dollars fighting the disease. This study examines the impact of the large amounts of federal funding allocated to U.S. cities to combat HIV/AIDS through the Ryan White CARE Act's first title. The findings indicate that the cost to avoid an HIV/AIDS death through the program is roughly $334,000, that the program has saved approximately 57,000 lives through 2018, and that funding disparities are responsible for the uneven progress in combating HIV/AIDS across the United States.

This table presents a wide variety of historical data in the field of health, lifestyle and health care. Figures on births and mortality, causes of death and the occurrence of certain infectious diseases are available from 1900, other series from later dates. In addition to self-perceived health, the table contains figures on infectious diseases, hospitalisations per diagnosis, life expectancy, lifestyle factors such as smoking, alcohol consumption and obesity, and causes of death. The table also gives information on several aspects of health care, such as the number of practising professionals, the number of available hospital beds, nursing day averages and the expenditures on care. Many subjects are also covered in more detail by data in other tables, although sometimes with a shorter history. Data on notifiable infectious diseases and HIV/AIDS are not included in other tables.

Data available from: 1900

Status of the figures:

2025: The available figures are definite.

2024: Most available figures are definite. Figures are provisional for: - notifiable infectious diseases, hiv, aids; - causes of death.

2023: Most available figures are definite. Figures are provisional for: - notifiable infectious diseases, HIV/AIDS; - diagnoses at hospital admissions; - number of hospital discharges and length of stay; - number of hospital beds; - health professions; - perinatal and infant mortality. Figures are revised provisional for: - expenditures on health and welfare.

2022: Most available figures are definite. Figures are provisional for: - notifiable infectious diseases, HIV/AIDS; - diagnoses at hospital admissions; - number of hospital discharges and length of stay; - number of hospital beds; - health professions. Figures are revised provisional for: - expenditures on health and welfare.

2021: Most available figures are definite. Figures are provisional for: - notifiable infectious diseases, HIV/AIDS; Figures are revised provisional for: - expenditures on health and welfare.

2020 and earlier: Most available figures are definite. Due to 'dynamic' registrations, figures for notifiable infectious diseases, HIV/AIDS remain provisional.

Changes as of 4 July 2025: The most recent available figures have been added for: - population on January 1; - live born children, deaths; - persons in (very) good health; - notifiable infectious diseases, HIV/AIDS; - diagnoses at hospital admissions; - use of medication; - sickness absence; - lifestyle; - use of health care services; - number of hospital discharges and length of stay; - number of hospital beds; - health professions; - expenditures on health and welfare; - healthy life expectancy; - causes of death.

Changes as of 18 december 2024: - Due to a revision of the statistics Health and welfare expenditure 2021, figures for expenditure on health and welfare have been replaced from 2021 onwards. - Revised figures on the volume index of healthcare costs are not yet available, these figures have been deleted from 2021 onwards.

When will new figures be published? December 2025.

BackgroundIn HIV infection, initiation of treatment is associated with improved clinical outcom and reduced rate of sexual transmission. However, difficulty in detecting infection in early stages impairs those benefits. We determined the minimum testing rate that maximizes benefits derived from early diagnosis. MethodsWe developed a mathematical model of HIV infection, diagnosis and treatment that allows studying both diagnosed and undiagnosed populations, as well as determining the impact of modifying time to diagnosis and testing rates. The model’s external consistency was assessed by estimating time to AIDS and death in absence of treatment as well as by estimating age-dependent mortality rates during treatment, and comparing them with data previously reported from CASCADE and DHCS cohorts. ResultsIn our model, life expectancy of patients diagnosed before 8 years post infection is the same as HIV-negative population. After this time point, age at death is significantly dependent on diagnosis delay but initiation of treatment increases life expectancy to similar levels as HIV-negative population. Early mortality during HAART is dependent on treatment CD4 threshold until 6 years post infection and becomes dependent on diagnosis delay after 6 years post infection. By modifying testing rates, we estimate that an annual testing rate of 20% leads to diagnosis of 90% of infected individuals within the first 8.2 years of infection and that current testing rate in middle-high income settings stands close to 10%. In addition, many differences between low-income and middle-high incomes can be predicted by solely modifying the diagnosis delay. ConclusionsTo increase testing rate of undiagnosed HIV population by two-fold in middle-high income settings will minimize early mortality during initiation of treatment and global mortality rate as well as maximize life expectancy. Our results highlight the impact of achieving early diagnosis and the importance of strongly work on improving HIV testing rates.

BackgroundHuman immunodeficiency virus (HIV) is one of the key factors contributing to global morbidity and mortality. Women of childbearing age (WCBA) represent a high-risk population for HIV/AIDS, presenting a substantial challenge to global public health systems. A comprehensive understanding of the AIDS burden in this demographic is essential for developing targeted screening and treatment strategies to effectively control mother-to-child transmission.MethodsUtilizing GBD 2021 data, this study systematically evaluated epidemiological trends in HIV/AIDS incidence, prevalence, mortality, and disability-adjusted life years (DALYs) among WCBA. The analysis employed a multidimensional stratification approach, examining temporal patterns, age distributions, geographic variations, and Socio-demographic Index (SDI). Additionally, a comprehensive analytical approach was employed, which included the estimated annual percentage change (EAPC), Joinpoint regression, decomposition analysis, and predictive modeling using the Nordpred method. Decomposition analysis quantified contributions from population growth, aging, and epidemiological changes.ResultsFrom 1990 to 2021, the numbers of incidence, prevalence, mortality, and DALYs of HIV/AIDS among WCBA increased significantly. In 2021, the global age-standardized rates for incidence (ASIR), prevalence (ASPR), mortality (ASMR), and DALYs (ASDALYR) were 34.73 (95% uncertainty interval [UI]: 30.03 to 40.54) per 100,000, 830.87 (95% UI: 784.57 to 884.29) per 100,000, 13.39 (95% UI: 10.34 to 17.56) per 100,000, and 829.75 (95% UI: 658.24 to 1,063.9) per 100,000, respectively. ASIR showed a downward trend, while ASPR exhibited an upward trend. Geographically, the highest persistent burden was observed in Sub-Saharan Africa. High-middle SDI region, Eastern Europe, and Pakistan had the fastest growth in incidence. Decomposition analysis showed that the increase in HIV/AIDS indicators among WCBA was mainly caused by population, and epidemiological changes. Nordpred analysis predicts modest decline in ASIR, ASPR, and ASMR by 2046.ConclusionFrom 1990 to 2021, substantial rise in incident cases, prevalent cases, mortality, and DALYs has established HIV/AIDS among WCBA as a critical global public health burden. This burden exhibits marked disparities across geographic regions, countries, and age groups. In high-burden areas, particularly Sub-Saharan Africa, public health practitioners must strengthen international cooperation and prioritize expanding HIV testing and antiretroviral therapy access, women’s empowerment, and removing socio-cultural barriers.

Estimated all-cause and cause-specific mortality rates by GBD and HIV disease classifications in Kisumu County, Kenya (2019).

The human immune virus (HIV) is a viral infection that destroys the human immune system resulting in acquired immunodeficiency syndrome (AIDS). If untreated, it can reduce the cluster of CD4 positive T-cells and increases the HIV viral load, thus causing AIDS. The Zambia HIV prevalence rate is among the highest in the sub-Saharan region. According to WHO, HIV/AIDS is a major cause of death in Zambia, with about a million deaths attributed to HIV/AIDS-related causes. With no HIV vaccine readily available and no permanent cure for HIV/AIDS, the antiretroviral (ARV) drug that slows the spread of the virus remains the only option. The ARV shuts down viral reproduction as well as reduces the immune suppression caused by HIV. Taking a combination of three ARV drugs from different classes suppresses the reproduction of the virus. The administration of ARV has challenges of Transmitted Drug Resistance Mutation strains (TDRMs) in the treatment of HIV naïve patients. In this article, we formulate a technique for determining an optimal ARV combination using Bayesian statistical methods. The proposed technique assist the medical personnel responsible in deciding the optimal ARV combination per patient in the presence of TDRMs test. We developed a transition probability matrix chart for each combination. Using the data from Zambia, we demonstrate the computation process and provide an interpretation of the obtained results. The findings from the analysis indicate that the probability of patients remaining on first baseline combinations namely, 1, 2, 3, 4, 5 and 6 are: 0.96, 0.99, 0.97, 0.91, 0.96, and 0.96 respectively. The probabilities obtained can be used to choose an optimal ARV combination in the presence of Transmitted Drug Resistance Mutation Strains because you can isolate the particular drugs which the patient is resistance.